Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03766581
Other study ID # CV010-031
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 27, 2019
Est. completion date March 31, 2022

Study information

Verified date June 2023
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.


Recruitment information / eligibility

Status Completed
Enrollment 2366
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Male and Female =40 years of age - Acute Ischemic Stroke or Transient Ischemic Attack - Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area Exclusion Criteria: - Predicted inability to swallow study medication - Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding - Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke Other protocol defined inclusion/exclusion criteria could apply

Study Design


Intervention

Drug:
BMS-986177
Oral administration
Other:
Placebo
Oral Administration
Drug:
Clopidogrel
Oral administration
Aspirin
Oral administration

Locations

Country Name City State
Argentina Local Institution - 0100 Adrogué Buenos Aires
Argentina Local Institution Buenos Aires
Argentina Local Institution Buenos Aires
Argentina Local Institution - 0068 Buenos Aires
Argentina Local Institution - 0063 Caba Buenos Aires
Argentina Local Institution - 0076 Caba Buenos Aires
Argentina Local Institution - 0067 Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina Local Institution - 0237 Lomas de Zamora Buenos Aires
Argentina Local Institution - 0435 Recoleta Buenos Aires
Argentina Local Institution Santa Fe
Australia Local Institution - 0399 Adelaide South Australia
Australia Local Institution - 0358 Clayton Victoria
Australia Local Institution - 0281 Heidelberg Victoria
Australia Local Institution - 0397 Launceston Tasmania
Australia Local Institution - 0315 Murdoch Western Australia
Australia Local Institution - 0329 Randwick New South Wales
Australia Local Institution - 0287 Southport Queensland
Australia Local Institution - 0360 Sydney New South Wales
Austria Local Institution - 0184 Klagenfurt Am Woerthersee
Austria Local Institution St. Pölten
Austria Local Institution - 0106 Vocklabruck
Austria Local Institution - 0273 Wien
Belgium Local Institution Brasschaat
Belgium Local Institution - 0284 Bruges
Belgium Local Institution - 0196 Brussel Brussels
Belgium Local Institution - 0190 Brussels
Belgium Local Institution - 0427 Brussels
Belgium Local Institution - 0305 Bruxelles
Belgium Local Institution - 0122 Edegem Antwerpen
Belgium Local Institution - 0199 Gent
Belgium Local Institution - 0103 Kortrijk
Belgium Local Institution - 0098 Leuven
Belgium Local Institution - 0178 Liege
Belgium Local Institution - 0192 Yvoir Namur
Brazil Local Institution - 0245 Botucatu SAO Paulo
Brazil Local Institution - 0065 Campinas SAO Paulo
Brazil Local Institution - 0314 Curitiba Parana
Brazil Local Institution - 0072 Fortaleza Ceara
Brazil Local Institution - 0219 Joinville Santa Catarina
Brazil Local Institution - 0200 Porto Alegre Rio Grande Do Sul
Brazil Local Institution Ribeirao Preto SAO Paulo
Brazil Local Institution - 0113 Santo Andre SAO Paulo
Brazil Local Institution - 0234 São Paulo SAO Paulo
Brazil Local Institution - 0248 São Paulo SAO Paulo
Brazil Local Institution - 0275 Uberaba Minas Gerais
Canada Local Institution - 0057 Calgary Alberta
Canada Local Institution - 0326 Chicoutimi Quebec
Canada Local Institution - 0061 Edmonton Alberta
Canada Local Institution - 0155 Greenfield Park Quebec
Canada Local Institution - 0054 Hamilton Ontario
Canada Local Institution Kingston Ontario
Canada Local Institution - 0059 Lethbridge Alberta
Canada Local Institution - 0227 London Ontario
Canada Local Institution - 0066 Montreal Quebec
Canada Local Institution - 0369 New Westminster British Columbia
Canada Local Institution - 0064 Quebec
Canada Local Institution Toronto Ontario
Canada Local Institution - 0124 Toronto Ontario
Canada Local Institution - 0121 Vancouver British Columbia
Chile Local Institution Los Angeles
Chile Local Institution - 0131 Valdivia
Chile Local Institution - 0167 Viña del Mar
Chile Local Institution - 0172 Viña del Mar Valparaiso
China Local Institution Beijing Beijing
China Local Institution Changchun Jilin
China Local Institution Daqing Heilongjiang
China Local Institution Guangzhou Guangdong
China Local Institution Haikou Hainan
China Local Institution Nantong Jiangsu
China Local Institution Qingdao Shandong
China Local Institution Shenyang Liaoning
China Local Institution Wenzhou Zhejiang
China Local Institution Yangzhou Jiangsu
China Local Institution YanTai Shandong
China Local Institution Zhengzhou Henan
Czechia Local Institution Brno
Czechia Local Institution Ceske Budejovice
Czechia Local Institution - 0348 Jihlava Vysocina
Czechia Local Institution - 0401 Olomouc Olomoucký Kraj
Czechia Local Institution - 0023 Ostrava
Czechia Local Institution - 0339 Praha 2
Denmark Local Institution - 0217 Aalborg
Denmark Local Institution - 0127 Aarhus N
Denmark Local Institution - 0142 Copenhagen
Denmark Local Institution - 0110 Glostrup
Denmark Local Institution - 0117 Herlev Capital
Finland Local Institution - 0111 Helsinki
Finland Local Institution - 0341 Lappeenranta
Finland Local Institution - 0143 Turku
France Local Institution - 0051 Bordeaux
France Local Institution Bourg-en-Bresse
France Local Institution - 0165 Brest
France Local Institution - 0174 Caen
France Local Institution Créteil
France Local Institution - 0048 Lille Nord
France Local Institution Limoges Cedex
France Local Institution - 0168 Marseille
France Local Institution - 0442 Montpellier Hérault
France Local Institution - 0297 Nancy
France Local Institution - 0205 Nimes
France Local Institution Paris
France Local Institution - 0028 Paris
France Local Institution - 0049 Paris
France Local Institution - 0126 Paris
France Local Institution - 0107 Rouen Cedex
France Local Institution - 0355 Toulouse Cedex 9
Germany Local Institution - 0011 Altenburg
Germany Local Institution Berlin
Germany Local Institution - 0032 Berlin
Germany Local Institution Bielefeld
Germany Local Institution - 0250 Bonn
Germany Local Institution - 0380 Bremen
Germany Local Institution - 0144 Dresden
Germany Local Institution - 0097 Erlangen
Germany Local Institution - 0053 Essen
Germany Local Institution - 0285 Frankfurt am Main Hessen
Germany Local Institution - 0291 Frankfurt am Main
Germany Local Institution - 0254 Gießen
Germany Local Institution - 0034 Hamburg
Germany Local Institution - 0044 Hamburg
Germany Local Institution - 0056 Hamburg
Germany Local Institution Hannover
Germany Local Institution - 0055 Heidelberg
Germany Local Institution - 0090 Leipzig Sachsen
Germany Local Institution - 0258 Lübeck Schleswig-Holstein
Germany Local Institution Magdeburg
Germany Local Institution - 0036 Minden
Germany Local Institution - 0256 Münster
Germany Local Institution - 0378 Osnabruck
Germany Local Institution - 0367 Regensburg
Germany Local Institution - 0387 Sande
Germany Local Institution Siegen
Germany Local Institution - 0391 Sindelfingen Baden-Württemberg
Germany Local Institution - 0045 Tübingen Baden-Württemberg
Germany Local Institution - 0241 Ulm
Greece Local Institution Athens
Greece Local Institution - 0209 Athens
Greece Local Institution - 0283 Athens
Greece Local Institution - 0351 Athens
Greece Local Institution - 0370 Athens
Greece Local Institution - 0373 Athens
Greece Local Institution - 0436 Athens
Greece Local Institution - 0440 Athens
Greece Local Institution - 0438 Athina Attiki
Greece Local Institution - 0407 Crete
Greece Local Institution Ioannina
Greece Local Institution - 0161 Larissa
Greece Local Institution - 0357 Larissa Larisa
Greece Local Institution - 0441 Larissa
Greece Local Institution - 0333 Loanniana
Greece Local Institution - 0365 Loanniana
Greece Local Institution - 0439 Neo Faliro
Greece Local Institution - 0371 Patras
Greece Local Institution - 0208 Pireaus
Greece Local Institution - 0210 Thessaloniki
Greece Local Institution - 0269 Thessaloniki
Greece Local Institution - 0389 Thessaloniki
Greece Local Institution - 0405 Thessaloniki
Greece Local Institution - 0444 Thessaloniki
Greece Local Institution - 0445 Thessaloniki
Hong Kong Local Institution Hong Kong
Hungary Local Institution - 0077 Budapest
Hungary Local Institution - 0119 Budapest
Hungary Local Institution - 0134 Budapest
Hungary Local Institution - 0136 Budapest
Hungary Local Institution - 0154 Debrecen
Hungary Local Institution - 0079 Gyor
Hungary Local Institution - 0175 Kistarcsa
Hungary Local Institution - 0437 Kisvárda
Hungary Local Institution - 0070 Miskolc BZ
Hungary Local Institution - 0220 Nyíregyháza
Hungary Local Institution - 0138 Pecs
Hungary Local Institution - 0133 Szeged
Hungary Local Institution - 0137 Zalaegerszeg
Israel Local Institution Beer-Sheva
Israel Local Institution - 0139 Haifa
Israel Local Institution - 0349 Haifa
Israel Local Institution Jerusalem
Israel Local Institution - 0078 Jerusalem
Israel Local Institution - 0193 Jerusalem
Israel Local Institution - 0308 Nahariya
Israel Local Institution - 0247 Petah Tikva
Israel Local Institution - 0204 Ramat-Gan
Israel Local Institution - 0086 Tel Aviv
Italy Local Institution - 0151 Ancona Marche
Italy Local Institution - 0156 Bologna
Italy Local Institution - 0290 Cagliari
Italy Local Institution - 0359 Genova Liguria
Italy Local Institution - 0095 Milano
Italy Local Institution - 0104 Modena
Italy Local Institution - 0149 Negrar Veneto
Italy Local Institution - 0084 Pavia Lombardia
Italy Local Institution - 0085 Perugia
Italy Local Institution - 0114 Perugia
Italy Local Institution - 0108 Roma
Italy Local Institution - 0129 Roma
Italy Local Institution - 0083 Verona
Italy Local Institution - 0123 Vibo Valentia
Japan Local Institution - 0257 Aizuwakamatsu-shi Fukushima
Japan Local Institution - 0337 Aki-gun Hiroshima
Japan Local Institution - 0232 Bunkyo-ku Tokyo
Japan Local Institution - 0320 Chikushino-shi Fukuoka
Japan Local Institution - 0243 Fukuoka
Japan Local Institution - 0271 Fukuoka
Japan Local Institution - 0343 Hachioji Tokyo
Japan Local Institution - 0263 Hidaka Saitama
Japan Local Institution - 0240 Higashihiroshima-shi Hiroshima
Japan Local Institution - 0328 Hiroshima-shi Hiroshima
Japan Local Institution - 0211 Isesaki-shi Gunma
Japan Local Institution - 0272 Izumisano-shi Osaka
Japan Local Institution - 0299 Kagoshima-shi Kagoshima
Japan Local Institution - 0323 Kanazawa Ishikawa
Japan Local Institution - 0259 Kasuga-shi Fukuoka
Japan Local Institution - 0335 Kasugai Aichi
Japan Local Institution - 0310 Kawasaki Kanagawa
Japan Local Institution - 0228 Kawasaki-city Kanagawa
Japan Local Institution Kishiwada Osaka
Japan Local Institution - 0311 Kitakyushu Fukuoka
Japan Local Institution - 0229 Kitakyushu-shi Fukuoka
Japan Local Institution - 0270 Kitakyushu-shi Fukuoka
Japan Local Institution - 0226 Kobe-City Hyogo
Japan Local Institution - 0230 Koga-shi Fukuoka
Japan Local Institution - 0446 Komatsu Ishikawa
Japan Local Institution - 0324 Kurume City Fukuoka
Japan Local Institution - 0312 Kyoto
Japan Local Institution - 0279 Matsubara Osaka
Japan Local Institution - 0255 Meguro-ku Tokyo
Japan Local Institution - 0338 Minato-ku Tokyo
Japan Local Institution - 0342 Minato-ku Tokyo
Japan Local Institution - 0295 Mitaka-shi Tokyo
Japan Local Institution - 0261 Nagasaki-shi Nagasaki
Japan Local Institution - 0274 Nagoya-shi Aichi
Japan Local Institution - 0239 Osaka
Japan Local Institution - 0313 Osaka
Japan Local Institution - 0327 Osaka
Japan Local Institution - 0301 Saga
Japan Local Institution - 0322 Sakai-shi Osaka
Japan Local Institution - 0336 Sakura-shi Chiba
Japan Local Institution - 0278 Sendai Miyagi
Japan Local Institution - 0296 Sendai-shi Miyagi
Japan Local Institution - 0319 Shimonoseki-Shi Yamaguchi
Japan Local Institution - 0334 Shimotsuke-shi Tochigi
Japan Local Institution - 0298 Shinagawa-ku Tokyo
Japan Local Institution - 0316 Shinjuku-ku Tokyo
Japan Local Institution - 0251 Suita Osaka
Japan Local Institution - 0244 Suita-shi Osaka
Japan Local Institution - 0318 Tachikawa-shi Tokyo
Japan Local Institution - 0309 Takayama-shi Gifu
Japan Local Institution - 0331 Toyoake Shi Aichi
Japan Local Institution - 0325 Toyohashi-shi Aichi
Japan Local Institution - 0317 Toyota-shi Aichi
Korea, Republic of Local Institution - 0081 Anyang
Korea, Republic of Local Institution - 0109 Busan
Korea, Republic of Local Institution - 0166 Busan
Korea, Republic of Local Institution Daegu
Korea, Republic of Local Institution - 0102 Daegu
Korea, Republic of Local Institution - 0179 Daegu
Korea, Republic of Local Institution - 0094 Goyang-si Gyeonggido
Korea, Republic of Local Institution - 0105 Gwangju
Korea, Republic of Local Institution - 0101 Incheon
Korea, Republic of Local Institution - 0153 Seongnam-si
Korea, Republic of Local Institution - 0071 Seoul
Korea, Republic of Local Institution - 0080 Seoul
Korea, Republic of Local Institution - 0087 Seoul
Korea, Republic of Local Institution - 0088 Seoul Seoul Teugbyeolsi
Korea, Republic of Local Institution - 0091 Seoul
Korea, Republic of Local Institution - 0112 Seoul
Korea, Republic of Local Institution - 0120 Seoul
Korea, Republic of Local Institution - 0145 Seoul
Korea, Republic of Local Institution - 0152 Seoul
Korea, Republic of Local Institution - 0185 Seoul
Mexico Local Institution Ciudad de Mexico Distrito Federal
Mexico Local Institution - 0394 Culiacan Sinaloa
Mexico Local Institution - 0366 Durango
Mexico Local Institution - 0396 Guadalajara Jalisco
Mexico Local Institution - 0398 Mexico Distrito Federal
Mexico Local Institution - 0404 Monterrey Nuevo LEON
Norway Local Institution - 0368 Bergen
Norway Local Institution - 0383 Grålum
Norway Local Institution Kristiansand
Norway Local Institution - 0130 Lørenskog
Norway Local Institution - 0408 Oslo
Norway Local Institution - 0330 Stavanger
Poland Local Institution - 0350 Bydgoszcz
Poland Local Institution - 0216 Chelm
Poland Local Institution - 0206 Gdansk
Poland Local Institution - 0181 Grodzisk Mazowieciki
Poland Local Institution - 0253 Katowice
Poland Local Institution Konskie
Poland Local Institution - 0197 Lodz
Poland Local Institution - 0198 Olsztyn
Poland Local Institution - 0215 Sandomierz
Poland Local Institution - 0183 Skarzysko-Kamienna
Poland Local Institution - 0225 Walcz
Poland Local Institution Warszawa
Poland Local Institution - 0214 Warszawa
Poland Local Institution - 0265 Warszawa Mazowieckie
Poland Local Institution - 0212 Wejherowo
Russian Federation Local Institution - 0277 Barnaul
Russian Federation Local Institution - 0260 Kemerovo
Russian Federation Local Institution Moscow
Russian Federation Local Institution - 0306 Moscow
Russian Federation Local Institution - 0268 Novosibirsk
Russian Federation Local Institution - 0202 Smolensk
Russian Federation Local Institution - 0356 St. Petersburg
Russian Federation Local Institution Yaroslavl
Spain Local Institution - 0141 A Coruna
Spain Local Institution - 0026 Albacete
Spain Local Institution - 0052 Badalona
Spain Local Institution - 0010 Barcelona
Spain Local Institution - 0012 Barcelona
Spain Local Institution - 0027 Barcelona
Spain Local Institution - 0385 Córdoba
Spain Local Institution - 0426 Girona
Spain Local Institution - 0176 L'Hospitalet de Llobregat
Spain Local Institution - 0372 León Castilla Y León
Spain Local Institution - 0249 Lleida
Spain Local Institution - 0025 Madrid
Spain Local Institution - 0238 Madrid
Spain Local Institution - 0384 Madrid
Spain Local Institution - 0413 Madrid
Spain Local Institution - 0159 Sabadell Barcelona
Spain Local Institution - 0400 San Sebastian
Spain Local Institution - 0163 Sant Joan Despi Barcelona
Spain Local Institution - 0425 Santiago de Compostela
Spain Local Institution - 0158 Sevilla
Spain Local Institution - 0177 Sevilla
Spain Local Institution - 0164 Tarragona
Spain Local Institution - 0150 Terrassa
Spain Local Institution - 0147 Valencia
Spain Local Institution - 0014 Valladolid
Spain Local Institution - 0418 Vigo
Sweden Local Institution - 0171 Göteborg
Sweden Local Institution - 0191 Hassleholm
Sweden Local Institution - 0128 Malmö Skane Lan
Sweden Local Institution - 0224 Umea
Sweden Local Institution - 0132 Uppsala
Switzerland Local Institution - 0162 Aarau
Switzerland Local Institution - 0118 Basel Basel-Stadt (de)
Switzerland Local Institution - 0115 Bern Bern (de)
Switzerland Local Institution - 0203 Geneve
Switzerland Local Institution - 0201 Lausanne
Switzerland Local Institution Zurich
United Kingdom Local Institution - 0140 Aberdeen
United Kingdom Local Institution Ashford
United Kingdom Local Institution - 0157 Bath
United Kingdom Local Institution - 0222 Canterbury Kent
United Kingdom Local Institution - 0089 Chester
United Kingdom Local Institution - 0221 Edinburgh
United Kingdom Local Institution - 0096 Glasgow
United Kingdom Local Institution - 0361 Lancashire
United Kingdom Local Institution London
United Kingdom Local Institution London
United Kingdom Local Institution - 0303 Luton
United Kingdom Local Institution Nottingham
United Kingdom Local Institution - 0431 Salford
United Kingdom Local Institution - 0414 Sheffield
United Kingdom Local Institution - 0307 Staffordshire
United States Local Institution - 0302 Abington Pennsylvania
United States Local Institution Allentown Pennsylvania
United States Local Institution - 0015 Augusta Georgia
United States Local Institution - 0008 Austin Texas
United States Local Institution - 0420 Baltimore Maryland
United States Local Institution - 0029 Birmingham Alabama
United States Local Institution Boston Massachusetts
United States Local Institution - 0236 Boston Massachusetts
United States Local Institution - 0354 Brooklyn New York
United States Local Institution Buffalo New York
United States Duke University Medical Center Butner North Carolina
United States Local Institution - 0276 Camden New Jersey
United States Local Institution Camp Hill Pennsylvania
United States Local Institution - 0043 Chapel Hill North Carolina
United States Local Institution - 0293 Chicago Illinois
United States University of Illinois Hospital & Health Sciences System Chicago Illinois
United States Local Institution - 0003 Cleveland Ohio
United States Local Institution - 0050 Cleveland Ohio
United States Local Institution - 0041 Columbia South Carolina
United States Local Institution - 0419 Columbus Ohio
United States Local Institution Dallas Texas
United States Neurology Consultants of Dallas, PA Dallas Texas
United States Local Institution Detroit Michigan
United States Local Institution Detroit Michigan
United States Local Institution - 0434 Detroit Michigan
United States University Medical center of El Paso El Paso Texas
United States Local Institution - 0430 Elk Grove Village Illinois
United States Local Institution - 0018 Erie Pennsylvania
United States Local Institution - 0375 Farmington Hills Michigan
United States Local Institution - 0075 Gainesville Florida
United States Local Institution - 0007 Glendale California
United States Advanced Neurology Specialists PLLC Great Falls Montana
United States Local Institution - 0016 Greensboro North Carolina
United States Local Institution - 0428 Honolulu Hawaii
United States Local Institution - 0040 Houston Texas
United States Local Institution - 0093 Houston Texas
United States Local Institution Kansas City Missouri
United States Local Institution - 0006 Long Beach California
United States Kaiser Permanente Los Angeles Medical Center Los Angeles California
United States Local Institution - 0231 Los Angeles California
United States Local Institution - 0346 Louisville Kentucky
United States Local Institution Milwaukee Wisconsin
United States Local Institution Minneapolis Minnesota
United States Local Institution - 0009 Nashville Tennessee
United States Local Institution - 0039 New Brunswick New Jersey
United States Local Institution - 0047 New Orleans Louisiana
United States Local Institution New York New York
United States Local Institution - 0125 New York New York
United States Local Institution - 0340 Newark Delaware
United States Local Institution - 0218 Oklahoma City Oklahoma
United States Local Institution - 0020 Philadelphia Pennsylvania
United States Temple University Hospital Philadelphia Pennsylvania
United States Local Institution - 0022 Portland Oregon
United States Local Institution Richmond Virginia
United States Local Institution - 0382 Rockford Illinois
United States Local Institution - 0376 Sacramento California
United States Local Institution Saint Louis Missouri
United States Local Institution - 0294 Saint Louis Missouri
United States Local Institution - 0352 Saint Louis Missouri
United States Local Institution - 0013 Sarasota Florida
United States Local Institution - 0004 Stanford California
United States Local Institution - 0024 Tampa Florida
United States Local Institution - 0187 Temple Texas
United States Local Institution - 0042 Torrance California
United States Local Institution Winston-Salem North Carolina
United States Local Institution - 0019 York Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Bristol-Myers Squibb Janssen, LP

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  Chile,  China,  Czechia,  Denmark,  Finland,  France,  Germany,  Greece,  Hong Kong,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Norway,  Poland,  Russian Federation,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Percent of Participants With Ischemic Stroke Events Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included. From randomization to up to 90 days after randomization
Primary Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90 Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples). From randomization to up to 90 days after randomization
Secondary Percent of Participants With Major Bleeding According to BARC Type 3 and 5 Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:
3a = Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop =5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding
From first dose to up to 107 days after first dose
Secondary Number of Participants With Bleeding Based on BARC Types 1-5 Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL. 3b=Overt bleeding plus hemoglobin drop =5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of =5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding. From first dose to up to 107 days after first dose
Secondary Number of Participants With Bleeding Based on ISTH-Defined Criteria Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of =2 g/dL, or leading to transfusion of =2 units of whole blood or red cells. From first dose to up to 107 days after first dose
Secondary Number of Participants With Bleeding Based on PLATO-Defined Criteria Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:
Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin >5 g/dL, Requiring transfusion of =4 U whole blood or packed red blood cells (PRBCs)
Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs
Any Major: Any one of the above criteria
Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention
From first dose to up to 107 days after first dose
Secondary Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90 Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90. From randomization to up to 90 days after randomization
Secondary Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death. From randomization to up to 90 days after randomization
Secondary National Institutes of Health Stroke Scale (NIHSS) The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is. At baseline, on Days 21 and 90, and at the time of a new stroke event
Secondary Modified Rankin Scale (mRS) The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.
0 = No symptoms at all
= No significant disability despite symptoms; able to carry out all usual duties and activities
= Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
= Moderate disability; requiring some help, but able to walk without assistance
= Moderately severe disability; unable to walk and attend to bodily needs without assistance
= Severe disability; bedridden, incontinent and requiring constant nursing care and attention
= Dead
At baseline, on Days 21 and 90, and at the time of a new stroke event
Secondary Montreal Cognitive Assessment (MoCA) The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:
=26 points: indicates normal cognitive function
18-25 points: Mild cognitive impairment
10-17 points: Moderate cognitive impairment
fewer than 10 points: Severe cognitive impairment
At baseline, on Days 21 and 90, and at the time of a new stroke event
Secondary Digit Symbol Substitution Test (DSST) The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning. At baseline, on Days 21 and 90, and at the time of a new stroke event
Secondary Number of Participants With Adverse Events (AEs) AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment. From first dose to 2 days after last dose of study therapy (up to approximately 107 days)
Secondary Number of Participants With Clinically Significant Vital Sign Abnormalities Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure. From first dose to up to 90 days after first dose
Secondary Number of Participants With Clinically Significant Physical Examination Abnormalities Number of participants with clinically significant physical examination abnormalities. From first dose to up to 90 days after first dose
Secondary Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities Number of participants with clinically significant ECG abnormalities. From first dose to up to 90 days after first dose
Secondary Number of Participants With Clinically Significant Laboratory Abnormalities - Liver The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.
Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)
From first dose to up to approximately 38 months
Secondary Percent Change From Baseline in aPTT Activity Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response. Baseline and day 90
Secondary Percent Change From Baseline in Factor XI Clotting Activity Percent change from baseline in factor XI clotting activity via exposure response. Baseline and day 90
Secondary Pharmacokinetic Parameter - Estimated Clearance (CL) Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90. From first dose to up to 90 days after first dose
Secondary Pharmacokinetic Parameter - Volume of the Central Compartment (VC) Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90. From first dose to up to 90 days after first dose
Secondary Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI. At day 90
Secondary Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI. At day 90
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3